Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share
Equities research analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to announce ($0.42) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.50). Aldeyra Therapeutics posted earnings of ($0.38) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.5%. The company is expected to announce its next quarterly earnings results on Monday, November 13th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.67) per share for the current fiscal year, with EPS estimates ranging from ($2.12) to ($1.43). For the next financial year, analysts expect that the company will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.49) to ($1.24). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02.
ALDX has been the subject of several research reports. Canaccord Genuity reissued a “buy” rating and set a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. Stifel Nicolaus reissued a “buy” rating and set a $16.00 price objective on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. ValuEngine raised Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $15.95.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of the firm’s stock in a transaction dated Friday, June 30th. The stock was acquired at an average price of $4.60 per share, with a total value of $1,361,632.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 28.40% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics in the second quarter worth $104,000. Renaissance Technologies LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $132,000. Hikari Power Ltd boosted its position in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the period. Sabby Management LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $898,000. Finally, Vanguard Group Inc. boosted its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares during the period. 49.09% of the stock is owned by institutional investors and hedge funds.
Aldeyra Therapeutics (NASDAQ:ALDX) traded down 17.59% during trading on Friday, hitting $8.90. The stock had a trading volume of 6,112,126 shares. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $11.90. The firm’s 50-day moving average price is $4.74 and its 200-day moving average price is $4.75. The stock’s market cap is $55.58 million.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.